Clinverse and ACRES announced a strategic alliance.
In their mutual goal to streamline clinical trial processes, Clinverse, a provider of automated financial management technology solutions for clinical trials, and the Alliance for Clinical Research Excellence and Safety (ACRES), a multi-sector non-profit dedicated to excellence in clinical research, announced a strategic alliance that brings Clinverse’s investigator payment solutions to ACRES global site network.
ACRES uses an alliance model spanning the clinical trial industry to construct an integrated system for the timely and cost-effective conduct of clinical research globally. ACRES alliance partners are developing an open access global network of clinical research sites, a shared technology platform, and standards and processes for accreditation, performance and quality metrics. Clinverse’s technology solutions, including flagship product ClinPay®, automatesthe financial management of clinical trials.
Read the full release here.
Real-World Data Show 99% Efficacy for Apretude in HIV Prevention with High Adherence, Reduced Stigma
October 16th 2024Real-world data presented at IDWeek 2024 show Apretude (cabotegravir long-acting) is more than 99% effective in preventing HIV infection, with high adherence rates, reduced stigma and anxiety, and broad acceptability.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zepzelca Plus Tecentriq Significantly Improves Survival in Extensive-Stage Small Cell Lung Cancer
October 15th 2024Preliminary data from the Phase III IMforte trial show the combination of Zepzelca (lurbinectedin) plus Tecentriq (atezolizumab) significantly improved overall survival and progression-free survival in patients with extensive-stage small cell lung cancer.